疑似早期胃癌的内镜黏膜下剥离术:西方大型队列中绝对与扩大适应证的比较
该研究在单一西方内镜中心前瞻性纳入121例患者共135处疑似早期胃癌及腺瘤性前驱病变,行内镜黏膜下剥离术(ESD),比较符合日本绝对与扩大适应证、超出适应证及仅含低级别上皮内瘤变者的结局。ESD整块切除率94.8%、R0切除率86.7%,穿孔率1.5%、术后出血率5.2%,随访中2处复发。作者认为ESD在西方背景下安全有效,拒绝手术或过于虚弱无法手术的超出适应证患者可能从ESD局部控制中获益。
要点
- 135处病变中62处(45.9%)符合扩大临床标准,107处(79.2%)达到内镜治愈的绝对或扩大标准。
- 整块切除率94.8%、R0切除率86.7%,穿孔率1.5%、术后出血率5.2%。
- 26例超出治愈标准患者中10例(38.5%)ESD后手术,3份标本检出残留肿瘤。
核心结论
- 作者认为ESD是西方背景下疑似早期胃癌及腺瘤性前驱病变的安全有效治疗。
- 作者认为拒绝手术或过于虚弱无法手术、切除超出适应证的患者可能从ESD局部疾病控制中获益。
- 作者提出需要大型西方ESD研究来定义长期患者结局和监测指南,尤其是病理仅显示低级别或高级别上皮内瘤变时。
研究设计与样本
- 前瞻性收集单一专家内镜中心所有接受ESD的疑似早期胃癌及腺瘤性前驱病变(pEGC)的数据,采用维也纳上皮内瘤变分类。
- 共纳入121例患者、135处pEGC,平均年龄72.0岁,男性61.2%,中位病变大小20 mm(四分位距15-30)。
- 由专科胃肠病理学家复核并分类所有ESD标本,患者在6个月和12个月随访。
- 比较符合日本绝对与扩大标准、超出标准及仅含低级别上皮内瘤变(LGD)的pEGC结局。
主要发现
- 71个月内135处pEGC接受ESD,62处(45.9%)符合扩大临床标准。
- 穿孔发生率1.5%,术后出血发生率5.2%。
- 42处pEGC(31.1%)仅含LGD。
- 整块切除率94.8%,R0切除率86.7%。
- 107处pEGC(79.2%)达到内镜治愈的绝对或扩大标准,随访中2处复发。
关键数值与推荐
- 26例超出治愈标准的pEGC患者中10例(38.5%)ESD后接受手术,3份标本检出残留肿瘤。
- 15例超出治愈标准的pEGC患者因虚弱或本人意愿未手术,其中11例已进行首次监测,1例(1/11)出现内镜和组织学复发。
- 中位pEGC大小20 mm(四分位距15-30),62处(45.9%)符合扩大临床标准。
临床怎么用
- 作者认为ESD是西方背景下pEGC的安全有效治疗。
- 作者认为拒绝手术或过于虚弱无法手术、切除超出适应证的pEGC患者可能从ESD局部疾病控制中获益。
- 作者提出需要大型西方ESD研究来定义长期患者结局和监测指南,尤其针对病理仅显示LGD或高级别上皮内瘤变者。
局限性
- 作者提出需要大型西方ESD研究来定义长期患者结局和监测指南,尤其当病理仅显示低级别或高级别上皮内瘤变时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) is an effective, minimally invasive, surgery-sparing technique for the treatment of early gastric cancer (EGC). It is not well established whether EGC within the Japanese expanded criteria can be safely and effectively treated using ESD in the West. We describe the outcomes of ESD for endoscopically suspected, biopsy specimen-confirmed EGC and its adenomatous precursor lesions (pEGC) using the Vienna classification of dysplasia in a Western cohort. METHODS: Prospective data were collected on all pEGCs undergoing ESD at a single expert endoscopy center. Outcomes were compared among pEGC, satisfying the Japanese absolute and expanded criteria, those outside criteria, and those specimens that contained low-grade dysplasia (LGD) only. Specialist GI pathologists reviewed and classified all ESD specimens. Patients were followed up at 6 and 12 months. RESULTS: Over 71 months, 135 pEGCs in 121 patients (mean age, 72.0 years; 61.2% men) underwent ESD. Median pEGC size was 20 mm (interquartile range, 15-30), and 62 (45.9%) satisfied the expanded clinical criteria. Perforation occurred in 1.5% and postprocedural bleeding in 5.2%. Forty-two pEGCs (31.1%) contained LGD only. Rates of en bloc and R0 resection were 94.8% and 86.7%, respectively. One hundred seven pEGCs (79.2%) met the absolute or expanded criteria for endoscopic cure. Two pEGCs recurred during follow-up. Ten of 26 patients with pEGC (38.5%) outside criteria for cure underwent surgery after ESD with residual tumor detected in 3 specimens. Fifteen patients with outside criteria for pEGCs did not undergo surgery because of frailty or their expressed wish. Eleven of 15 patients have so far undergone first surveillance with 1 of 11 experiencing endoscopic and histologic recurrence. CONCLUSIONS: ESD is a safe and effective treatment for pEGCs in a Western context. Patients who either decline or are too frail for surgery, with outside criteria resections, may benefit from ESD for local disease control. Large Western studies of ESD for pEGCs are required to define long-term patient outcomes and surveillance guidelines, particularly where pathology shows LGD or high-grade dysplasia only. (Clinical trial registration number: NCT02306707.).
引用
- Tate DJ, Klein A, Sidhu M, et al. Endoscopic submucosal dissection for suspected early gastric cancer: absolute versus expanded criteria in a large Western cohort (with video). Gastrointest Endosc. 2019. PMID: 31077699. doi:10.1016/j.gie.2019.04.242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。